GACOS: Revenue for 2025 is expected to decrease to 53.5 million yuan, with multiple product pipelines advancing and expected to bring new growth opportunities.

LightningPacketLoss · 2026-03-11T23:40:16+00:00

Gaceta released the 2025 performance report, with revenue significantly decreasing to 53.5 million yuan and gross profit dropping to 52.9 million yuan, mainly due to reductions in licensing agreements and clinical trial services. R&D expenses decreased by 42.9%, and administrative expenses fell by 20.2%. The company is actively advancing its KRAS and ADC products, with its core product, AiReKai®, already approved for market listing, which is expected to bring new growth in the future.

LightningPacketLoss

2026-03-11 23:40:16

Abstract generation in progress

Recently, Jaco Bio released its annual performance report for the year ending December 31, 2025. During the reporting period, the company recorded revenue of 53.5 million yuan, a significant decrease from 156 million yuan in 2024, mainly due to reduced income related to licensing agreements and associated clinical trial services. Gross profit dropped from 156 million yuan to 52.9 million yuan, primarily due to the decrease in revenue. Additionally, other income fell from 14.3 million yuan to 3.8 million yuan, mainly due to a reduction in government subsidies.

R&D expenses decreased sharply by 42.9%, from 330 million yuan as of December 31, 2024, to 189 million yuan, mainly because there were no large-scale costs for key clinical trials during the reporting period, including clinical trial drug supplies. Administrative expenses also decreased by 20.2%, from 43.1 million yuan to 34.4 million yuan, mainly due to lower employee benefits and controlled miscellaneous expenses.

In terms of business segments, the company continued to advance its KRAS and ADC product pipelines. Arecain® (KRASG12C) received market approval in May 2025 and became one of the company’s core products. Additionally, the development of JAB-23E73 (pan-KRAS) in collaboration with AstraZeneca is ongoing, expected to bring new growth opportunities in the future.

(Jaco Bio Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.